Over 13 years’ experience in delivering market access strategic consulting and intelligence.
Louise brings a breadth of experience across commercial potential assessment, product value messaging, and pricing and reimbursement.
What’s the most rewarding part of your role?
The most rewarding part of my role is knowing that the work I do has a direct impact on shaping the future of new medicines. Helping clients make informed strategic decisions that could ultimately improve or even save patients’ lives is a real privilege.
What’s a project you’re particularly proud of, and why?
Recently, I worked with a client on their submission for Orphan Drug Designation (ODD) to the EMA. It was a complex project that was a collaborative effort, and although we’re still waiting on the outcome, I’m proud of how we helped our client bring together regulatory, scientific, and strategic thinking to build a compelling case. This project was exactly the kind of work that reminds me why I love what I do!
What’s one thing you bring to a team that people might not see on paper?
I like to think I have an ability to see the bigger picture which means I can help others connect the dots in a practical and logical way. The work I do ultimately helps to bridge the gap between deeply technical data and information and its strategic implications, which is especially useful when we’re working cross-functionally with clients or even internally across VISFO’s different teams.
What excites you most about the direction of VISFO right now?
The thing that has always excited me about VISFO and is ultimately what drove me to want to become part of the VISFO team is our blend of data, science and tech. VISFO truly sits at the intersection of strategic consultancy and innovative product development, which for me is what really sets VISFO apart, as that is not something you see every day. The potential to deliver not just advice but actual tools that empower clients to make better decisions, faster, is hugely exciting.
What’s your go-to approach when solving a difficult problem?
Always start with (and perhaps more importantly DO NOT lose sight of) the question: what is the decision that needs to be made? From there, it’s about breaking down the problem, getting the right data, asking the right questions along the way, and making sure we’re looking at it from all the right angles.
What would we find you doing outside of work?
In my “spare time” I’m almost always in the middle of organising the latest school disco, quiz night or a summer fayre as a core member of the PTFA at my boys’ primary school. I’m also a keen cake decorator although these days, it’s mostly birthday cakes for family, made late at night when (hopefully) the house is quiet! When we do have true chill out time as a family you can usually find us exploring one of the countries many National Trust properties!
Louise completed her doctoral research at The University of Sheffield, and her work centred around the study of a group of proteins called Tribbles (specifically Trb2), which are involved in how cells communicate and respond to signals and seem to play important roles in many cell processes. Louise's research involved a broad range of molecular biology techniques, including cell culture, gateway cloning, transfection, flow cytometry, fluorescence microscopy, immunoprecipitation, and western blotting, through which she developed strong expertise in experimental design and data analysis
Louise’s research focused on the identification and investigation of a novel protein–protein interaction between two proteins, Trb2 and Gab1 that hadn’t been reported before, and showed that this interaction is influenced by a key cell signalling pathway known as PI3K/Akt. Louise also looked at how this interaction affects the cell’s internal structure (specifically the actin cytoskeleton) which is important for things like cell shape, movement, and communication. Overall, the research provided new insights into how Trb2 might influence important cell behaviours which could be key to understanding disease pathways and highlighted Trb2’s potential as a target for future therapies.